Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT05162326
PHASE1
BC-101 in Treatment of Nasolabial Fold Wrinkles
Sponsor: Bright Cell, Inc.
View on ClinicalTrials.gov
Summary
This is an open-label, single-arm, dose-escalating study to evaluate the safety and tolerability of BC-101 administered via subcutaneous/intradermal injection in the treatment of moderate to severe nasolabial folds.
Official title: A Phase 1/2 Study of the Safety and Efficacy of BC-101 in Treatment of Nasolabial Fold Wrinkles Via Subcutaneous/Intradermal Injection
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2026-12-01
Completion Date
2028-02-20
Last Updated
2025-12-29
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
BC-101
Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.